Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

7 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
In vivo models and decision trees for formulation development in early drug development: A review of current practices and recommendations for biopharmaceutical development.
Zane P, Gieschen H, Kersten E, Mathias N, Ollier C, Johansson P, Van den Bergh A, Van Hemelryck S, Reichel A, Rotgeri A, Schäfer K, Müllertz A, Langguth P. Zane P, et al. Among authors: van hemelryck s. Eur J Pharm Biopharm. 2019 Sep;142:222-231. doi: 10.1016/j.ejpb.2019.06.010. Epub 2019 Jun 21. Eur J Pharm Biopharm. 2019. PMID: 31233862 Review.
Clinical pharmacokinetics, pharmacodynamics, safety, and tolerability of JNJ-54175446, a brain permeable P2X7 antagonist, in a randomised single-ascending dose study in healthy participants.
Timmers M, Ravenstijn P, Xi L, Triana-Baltzer G, Furey M, Van Hemelryck S, Biewenga J, Ceusters M, Bhattacharya A, van den Boer M, van Nueten L, de Boer P. Timmers M, et al. Among authors: van hemelryck s. J Psychopharmacol. 2018 Dec;32(12):1341-1350. doi: 10.1177/0269881118800067. Epub 2018 Sep 27. J Psychopharmacol. 2018. PMID: 30260294 Clinical Trial.
Bioequivalence of a Pediatric Fixed-Dose Combination Tablet Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Compared With Coadministration of the Separate Agents in Healthy Adults: An Open-Label, Randomized, Replicate Crossover Study.
Van Hemelryck S, Van Landuyt E, Ariyawansa J, Vanveggel S, Palmer M. Van Hemelryck S, et al. Clin Pharmacol Drug Dev. 2023 Nov;12(11):1060-1068. doi: 10.1002/cpdd.1293. Epub 2023 Jun 19. Clin Pharmacol Drug Dev. 2023. PMID: 37335552 Clinical Trial.